Login to Your Account



Pfizer Keeping the ADC Faith: Potential $635M CytomX Deal

By Randy Osborne
Staff Writer

Thursday, June 6, 2013

CytomX Therapeutics Inc.'s oncology deal with Pfizer Inc. to develop Probody-drug conjugates gives the pharma giant rights to develop selected candidates in exchange for a potential $25 million up front, as well as $610 million if regulatory and sales milestones are met.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription